Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLUE NASDAQ:CRGX NYSE:CYBN NASDAQ:DSGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUEbluebird bio$4.97$4.73$3.20▼$28.60$48.67M0.27444,851 shsN/ACRGXCARGO Therapeutics$4.60+0.4%$4.27$3.00▼$25.45$212.11M0.28694,215 shs5.18 million shsCYBNCybin$7.52-1.4%$7.66$4.81▼$13.88$173.14M0.69281,604 shs265,869 shsDSGNDesign Therapeutics$4.17+14.6%$3.82$2.60▼$7.77$236.73M1.56178,258 shs248,717 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUEbluebird bio0.00%0.00%0.00%+2.47%-73.44%CRGXCARGO Therapeutics+4.33%+9.31%-3.58%+13.09%-71.38%CYBNCybin-3.05%-15.22%-14.27%+40.77%+1,967.75%DSGNDesign Therapeutics+2.82%+3.41%-9.23%+22.97%+4.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUEbluebird bio2.0993 of 5 stars3.10.00.00.01.41.71.3CRGXCARGO Therapeutics2.0905 of 5 stars2.90.00.00.01.91.71.3CYBNCybin2.9135 of 5 stars3.60.00.00.03.10.81.3DSGNDesign Therapeutics0.3701 of 5 stars1.01.00.00.00.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUEbluebird bio 2.25Hold$44.60797.38% UpsideCRGXCARGO Therapeutics 1.86Reduce$15.40234.78% UpsideCYBNCybin 3.25Buy$85.001,030.32% UpsideDSGNDesign Therapeutics 2.00Hold$4.00-4.08% DownsideCurrent Analyst Ratings BreakdownLatest BLUE, CYBN, DSGN, and CRGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025CRGXCARGO TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$3.70 ➝ $5.007/8/2025CYBNCybinCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$73.00 ➝ $70.005/13/2025CYBNCybinCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14CRGXCARGO TherapeuticsN/AN/AN/AN/A$7.83 per shareN/ACYBNCybinN/AN/AN/AN/A$10.83 per shareN/ADSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%8/12/2025 (Estimated)CRGXCARGO Therapeutics-$167.50M-$4.62N/AN/AN/AN/A-45.93%-39.58%8/11/2025 (Estimated)CYBNCybin-$57.88M-$3.88N/AN/AN/AN/A-37.58%-36.59%N/ADSGNDesign Therapeutics-$49.59M-$0.99N/AN/AN/AN/A-22.85%-22.02%8/4/2025 (Estimated)Latest BLUE, CYBN, DSGN, and CRGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q1 2025DSGNDesign Therapeutics-$0.32N/AN/AN/AN/AN/A5/14/2025Q1 2025DSGNDesign Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUEbluebird bioN/AN/AN/AN/AN/ACRGXCARGO TherapeuticsN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUEbluebird bio0.370.510.33CRGXCARGO TherapeuticsN/A6.306.30CYBNCybinN/A24.2424.24DSGNDesign TherapeuticsN/A28.3728.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUEbluebird bio87.43%CRGXCARGO Therapeutics93.16%CYBNCybin17.94%DSGNDesign Therapeutics56.64%Insider OwnershipCompanyInsider OwnershipBLUEbluebird bio1.40%CRGXCARGO Therapeutics2.92%CYBNCybin15.00%DSGNDesign Therapeutics31.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableCRGXCARGO Therapeutics11646.11 million44.76 millionN/ACYBNCybin5023.02 million17.96 millionNot OptionableDSGNDesign Therapeutics4056.77 million39.06 millionOptionableBLUE, CYBN, DSGN, and CRGX HeadlinesRecent News About These CompaniesDesign Therapeutics, Inc. Reports Initial Safety Data for DT-216P2 in Friedreich Ataxia Trial Amid FDA Clinical Hold on U.S. IND ApplicationJune 4, 2025 | quiverquant.comQDesign Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2June 4, 2025 | globenewswire.comDesign Therapeutics to Participate in 2025 Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comDesign Therapeutics to Participate in 2025 RBC Capital Markets Healthcare ConferenceMay 13, 2025 | globenewswire.comDesign Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial ResultsMay 7, 2025 | globenewswire.comDesign Therapeutics To Initiate Phase 2 Biomarker Trial Of DT-168 In FECD In 2H 2025May 3, 2025 | nasdaq.comDesign Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal DystrophyMay 1, 2025 | globenewswire.comWhy Design Therapeutics, Inc.’s (DSGN) Stock Is Down 5.42%April 25, 2025 | aaii.comADesign Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025April 22, 2025 | nasdaq.comDesign Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025April 21, 2025 | globenewswire.comDesign Therapeutics appoints Chris Storgard as CMOApril 18, 2025 | markets.businessinsider.comDesign Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical OfficerApril 17, 2025 | globenewswire.comBright Peak Therapeutics Appoints John Schmid to its Board of DirectorsApril 17, 2025 | markets.businessinsider.comDesign Therapeutics (DSGN) Upgraded to Buy: Here's WhyMarch 12, 2025 | zacks.comWall Street Analysts See a 31.33% Upside in Design Therapeutics (DSGN): Can the Stock Really Move This High?March 12, 2025 | msn.comDesign Therapeutics price target raised to $5 from $4 at RBC CapitalMarch 11, 2025 | markets.businessinsider.comDesign Therapeutics (DSGN) Gets a Hold from RBC CapitalMarch 11, 2025 | markets.businessinsider.comDesign Therapeutics sees cash runway into 2029March 10, 2025 | markets.businessinsider.comDesign Therapeutics provides corporate highlights, anticipated milestonesMarch 10, 2025 | markets.businessinsider.comDesign Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 10, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonDon’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonBy Chris Markoch | July 8, 2025View Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonOuster Soars 27% as DoD Grants First 3D LiDAR Approval for DronesBy Leo Miller | June 14, 2025View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones3 Tech Focused ETFs to Watch as the Market Nears All-Time HighsBy Ryan Hasson | June 11, 2025View 3 Tech Focused ETFs to Watch as the Market Nears All-Time Highs5 High-Yielding ETFs to Buy and Hold ForeverBy Ryan Hasson | June 30, 2025View 5 High-Yielding ETFs to Buy and Hold ForeverBLUE, CYBN, DSGN, and CRGX Company Descriptionsbluebird bio NASDAQ:BLUE$4.97 0.00 (0.00%) As of 06/2/2025bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.CARGO Therapeutics NASDAQ:CRGX$4.60 +0.02 (+0.44%) Closing price 04:00 PM EasternExtended Trading$4.60 0.00 (-0.11%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Cybin NYSE:CYBN$7.52 -0.11 (-1.44%) Closing price 04:00 PM EasternExtended Trading$7.55 +0.03 (+0.40%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Design Therapeutics NASDAQ:DSGN$4.17 +0.53 (+14.56%) Closing price 04:00 PM EasternExtended Trading$4.16 -0.01 (-0.24%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
